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Dr Carl L. Backer (Chicago, Ill). I want to congratulate Dr
Chen and his colleagues from Children’s Hospital of Boston on
their outstanding results with PVR in children and young adults
with repaired TOF. A total of 229 operations with no mortality
and no significant morbidity is truly a notable achievement.
I believe this review is timely for 2 reasons. One is our current
emphasis on pulmonary valve preservation during the initial TOF
repair. The fact that 229 patients were believed to need PVR after
TOF repair emphasizes the importance of pulmonary valve preser-
vation, if possible, at the time of the initial operation.
The second reason this presentation is quite timely is the current
increase in the use of transcatheter pulmonary valve insertion for
appropriate patients. This leads me to my first of 3 questions.
It is my impression in our practice that the availability of trans-
catheter pulmonary valve insertion has actually led to an increase
in the number of referrals for surgical PVR. The placement of a sur-
gical valve gives the interventional cardiologist a future landing358 The Journal of Thoracic and Cardiovascular Surgsite for their transcatheter valve. This changes the treatment para-
digm from valve deterioration, leading not to another operation but
to a transcatheter intervention. My first question then is this: Has
the introduction of the percutaneous pulmonary valve changed
your management paradigm for these patients?
Dr Chen. Thank you very much for the comments and the
question.
Regarding whether the criteria for pulmonary valve reinterven-
tion differ with the advent of transcatheter valves, I do not believe
there is a difference. The same indications for valve reintervention,
namely symptomatic PR or an RVEDVI of greater than 150ml/m2,
apply for surgical PVR, as well as transcatheter valve replacement.
I would have to say that the criteria have definitely changed over
the duration of our study period toward earlier reintervention and
in patients with even mild RV dilation. However, these guidelines
again hold for both surgical and transcatheter valve replacement at
our institution.
Dr Backer. My second question is directly tied to the title of
your article, which was somewhat provocative. If younger age is
a predictor of SVD, are you now delaying some pulmonary valve
operations despite, for example, an RVEDV of 160 mL/m2? For
a patient like that who is, for example, 14 or 15 years old, would
you now wait until they are older to place the valve? In other
words, is this finding in your article a statistical anomaly, or is it
truly something that is going to have a clinical effect?
Dr Chen. I believe our findings could potentially have some
significant clinical effect in the future. However, despite the find-
ings, currently, we would not necessarily endorse delaying surgi-
cal intervention. At our institution, practices have not changed
despite our study results. Again, as you stated, the primary goal
is preservation of RV function. If the debate is between whether
you want to deal with earlier valve deterioration and an extra op-
eration versus the complications that come with chronic pulmo-
nary insufficiency and RV dilatation, specifically arrhythmias
and sudden death, I think the majority would not delay surgical in-
tervention. Therefore because of the potential complications asso-
ciated with delaying reintervention, our practices have not
changed.
On the basis of our results, we do believe that attention should
be placed on developing a systematic approach to defining the op-
timal timing of reintervention and weighing the advantages and
disadvantages of delaying surgical intervention. In addition, we
believe greater attention should be paid to avoiding oversizing,
which was a newer finding in our study. In particular, we will
plan to look more closely at the possibility that valve oversizing
in relation to body surface area might be contributing to the earlier
valve failure seen in our reintervention group.
Dr Backer. My final question relates to the technical details of
this operation. Some surgeons routinely do this with aortic cross-
clamping, and some do this with a beating heart. For many years,
our standard approach has been to use a crossclamp for these pa-
tients. We only use a beating-heart strategy in a very complicated
reoperation with difficult dissection after a careful bubble study
with Valsalva at the beginning of the case with transesophageal
echocardiographic analysis showing no evidence of any intracar-
diac shunts. Reading your article, you had no neurologic compli-
cations in this series. Whatever your surgical strategy was, it
was quite a good one, and perhaps you would like to share withery c February 2012
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Dus your guideline regarding the indications for crossclamp versus
beating-heart surgery for pulmonary valve insertion.
Again, I congratulate you on your outstanding results and excel-
lent presentation.
Dr Chen. The practices differ between the surgeons; however,
typically, if there is any residual shunt, these are captured on
a preoperative catheterization in which the cardiologist specifi-
cally probes for a patent foramen ovale or during an intraoperative
transesophageal echocardiogram with a bubble study, as you men-
tioned. In these cases in which a residual shunt is identified, cross-
clamping would be used.
In addition, crossclamping can be used for better exposure. Oth-
erwise, we do not necessarily use crossclamping in all patients un-
dergoing a PVR.
Dr J. William Gaynor (Philadelphia, Pa). I would like to ask
one question about the mechanisms of the valve failure. The youn-
ger age would suggest that perhaps this is an accelerated calcifica-
tion of the leaflets with degeneration. The oversizing would
suggest that perhaps there is distortion of the struts. Do you have
any data on the mechanisms of a failure when they differ for those
that fail in the younger patients versus those with the oversized
valves?
Dr Chen. Aside from whether the primary mode of valve fail-
ure was PR or PS, we do not have any additional data. As I men-
tioned, the majority of the patients had echocardiographic or MRI
evidence of PR before reintervention. Some patient had a combina-
tion of both regurgitation and stenosis.
Dr Gaynor. Was there leaflet deterioration or distortion of the
struts in any of the valves before explantation?
DrChen. Unfortunately, we do not have that information today;
however, looking more specifically at individual operative notes
would be very useful in determining this.
Dr Richard A. Jonas (Washington, DC). I rise to reinforce the
point that Carl Backer was just making about the risks of neuro-
logic injury. I am sure some of the people in this room have
been asked to review cases of severe brain injury or death that
have occurred in the not-too-distant past as we do more and
more of these PVRs. It is for sure an important risk if the operation
is done with a beating heart.
The problem is often entrainment of air. For example, if you cut
into the original outflow patch as you are reopening the sternum
and you get frothing in the right heart from the heart action, then
that froth can be drawn through the foramen ovale with the heart
continuing to beat. Or if you are using a single venous cannula
or 2-stage cannula and you are entraining air through the tricuspid
valve and the heart is continuing to beat, you can definitely get
enough air into the left side to cause severe brain injury.
Therefore another option, if you are not confident, as I am not,
that a transesophageal echocardiogram is always going to show
you a right-to-left shunt at the atrial level through a foramen ovale,
is to use electrical fibrillation. We find that that this is the best way
to do this operation. You do not have to dissect out the aorta. In
fact, I am using more and more electrical fibrillation. You can
do it at relatively mild hypothermia. Therefore this is my question
for you: Are you using ventricular fibrillation?
Dr Chen. Unfortunately, I might have to defer this question to
Dr Pigula, who is here representing the group. I cannot comment
on that.The Journal of Thoracic and CaDr Frank Pigula (Boston, Mass). I agree completely with ev-
erything you said, and we do use electrical fibrillation. We have
a very low threshold for either crossclamping or using electrical fi-
brillation if there is any question regarding the status of the atrial
septum. Because the transesophageal echocardiogram is not 100%
sensitive, I am not willing to bet somebody’s life on it.
I just want to take this moment to make a couple of other com-
ments regarding the mode of failure of these valves. I think it is im-
portant because of the introduction of the percutaneous valve.
There might be implications for how the current generation of sur-
gically implanted valve fails and how suitable it will be for a trans-
catheter valve in the future. In other words, if it were a stenotic
failure or a collapse of the struts, that might have a different impli-
cation on a transcatheter valve than a valve failing because of re-
gurgitation. Also, we have not really seen valves that have failed
from strut collapse or stenosis in these patients.
Over time, our indications have changed. The cardiologists and
we do use the same indications for valve placement, and that is
usually at an end-diastolic volume of about 150 mL/m2.
However, I do think that our criteria for PVR has changed, and
the availability of a percutaneous valve might have influenced that.
DrAliMumtaz (Norfolk, Va). My question is very brief regard-
ing theMitroflow valve. I noticed you have a very large experience
with that. There was one slide that showed that something was sta-
tistically significant in this group of patients. Just out of curiosity,
of the 58 valves you used, how many of them failed in that 1-year
follow-up?
Dr Chen. There were a total of 4 patients within the Sorin Mi-
troflow group who fit our criteria for SVD. There were no reinter-
ventions in this group.
Dr Mumtaz. That is a significant failure for just 1 year. I have
found the same thing in the CE bovine pericardial valve; there is an
incidence of early failure in the pulmonary position. That is why I
was curious to ask if that is any different.
DrChen. Therewere 4 patients of our 58 in the SorinMitroflow
group who had the criteria of valve deterioration, none of whom
required reintervention. However, it would be very interesting to
look at each patient and identify a specific mode of early valve
failure.
Dr Jonathan Chen (New York, NY). This might be a question
for Frank, too, given that the primary mode of failure was
regurgitation, and given that we are assuming that this valve-
inside-of-a-valve percutaneous strategy will work in the future. I
used to always try to oversize these pulmonary prostheses as big
as we could, thinking that the mode of failure was going to be
a combination of stenosis and regurgitation and that the actual in-
ternal orifice was going to get smaller and smaller, and therefore
they ultimately were going to be able to put a Melody valve inside.
For example, if you put a 29-mm valve in the orthotopic position,
then perhaps it could one day provide the support structure for
a 25-mm Melody valve.
But now I am told by our interventionalists that the SAPIEN
valve is the only one that is as big as 27mm. Therefore the question
is this: If it is mostly regurgitation and not stenosis, should we be
putting in any valves that are over size 27 mm?
Dr Pigula. I will answer that one. I think that one of the take-
home messages I have from this is that oversizing the valve is
not necessarily an advantage. For most patients, a 25-mm valverdiovascular Surgery c Volume 143, Number 2 359
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Dis large enough and provides a suitable landing zone for the current
generation of percutaneous valves.
The other information, and I think Bill brought it up, is whether
it is calciummetabolism that is leading to the valve deterioration in
younger patients or whether it is the fact that those valves are over-
sized for younger and smaller patients. Therefore I have gone to
just sizing a 25-mm valve unless there is an obvious reason to
use something larger.
Dr Frank L. Hanley (Stanford, Calif). I just had a few more
thoughts about the beating heart and the potential for neurologic
injury. It is clearly an extremely important point because it can
be devastating.
We did a little study many, many years ago in which we did bub-
ble studies on the right side and then obligatorily had to open the
heart in a certain percentage of those patients, and we checked spe-
cifically for patent foramen ovale. Of all of the patients who had
a negative bubble study result, I think we found patent foramen
ovale in 25% or 30%. Therefore it is clearly not a complete
safeguard.360 The Journal of Thoracic and Cardiovascular SurgHowever, we routinely do all of these cases on a warm beating
heart. What we do is the bubble study; we do a left-sided and
right-sided bubble study. Even then, if the results of both of those
are negative, wewill proceed with a warm beating-heart procedure.
However, I specifically look the anesthesia fellow in the eye-and I
guess you have to have the luxuryof having at least 2 anesthesia peo-
ple-but I look the anesthesia fellow in the eye and say, ‘‘As long as
this right ventricle is open, don’t take your eyes off that echo ma-
chine.’’ At even the first bubble that goes across, we will then abort
and do something else. Most of the time, you are fine; occasionally,
you will see 1 or 2 bubbles come across, and then you can make
a change. But if you do that, you have a very, very complete safe-
guard, and you can domost of these on awarmbeating heart, I think.
Dr Pigula. The only thing I wanted to add to Dr Hanley’s com-
ments is that the other thing I will ask the anesthesiologist to do is
make sure the perfusion pressure stays up to keep the aortic valve
closed during the case. Therefore I will always ask them to leave it
at maybe an extra 10 mmHg higher to give me a little extra margin
of safety and to prevent the ventricle for injecting.ery c February 2012
